These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 29630519
1. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer. Baek AR, Seo HJ, Lee JH, Park SW, Jang AS, Paik SH, Koh ES, Shin HK, Kim DJ. Cancer Biomark; 2018; 22(1):55-62. PubMed ID: 29630519 [Abstract] [Full Text] [Related]
3. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. Jiang AG, Chen HL, Lu HY. BMC Cancer; 2015 May 10; 15():386. PubMed ID: 25956656 [Abstract] [Full Text] [Related]
4. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer. Szturmowicz M, Rudziński P, Kacprzak A, Langfort R, Bestry I, Broniarek-Samson B, Orłowski T. Pneumonol Alergol Pol; 2014 May 10; 82(5):422-9. PubMed ID: 25133810 [Abstract] [Full Text] [Related]
6. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients]. Duan X, Cui Y, Gong M, Tian F, Shi G, Wu B, Liu M, Guo J, Kong Y. Zhongguo Fei Ai Za Zhi; 2015 Jun 10; 18(6):358-64. PubMed ID: 26104892 [Abstract] [Full Text] [Related]
10. The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer. Li L, Xu Y, Wang Y, Zhang Q, Wang Y, Xu C. Technol Cancer Res Treat; 2024 Jun 10; 23():15330338241265983. PubMed ID: 39043046 [Abstract] [Full Text] [Related]
11. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. Lung Cancer; 1995 Oct 10; 13(2):169-76. PubMed ID: 8581396 [Abstract] [Full Text] [Related]
13. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Zhang Z, Yuan F, Chen R, Li Y, Ma J, Yan X, Wang L, Zhang F, Tao H, Guo D, Huang Z, Zhang S, Li X, Zhi X, Ge X, Hu Y, Wang J. Front Immunol; 2020 Oct 10; 11():1173. PubMed ID: 32587591 [Abstract] [Full Text] [Related]
14. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Zhang ZH, Han YW, Liang H, Wang LM. Cancer Med; 2015 Nov 10; 4(11):1633-8. PubMed ID: 26333429 [Abstract] [Full Text] [Related]
17. Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients. Sone K, Oguri T, Ito K, Kitamura Y, Inoue Y, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Asano T, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A. Anticancer Res; 2017 Sep 10; 37(9):5125-5131. PubMed ID: 28870944 [Abstract] [Full Text] [Related]
20. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O. Anticancer Res; 2014 Jun 10; 34(6):3205-10. PubMed ID: 24922695 [Abstract] [Full Text] [Related] Page: [Next] [New Search]